Bausch + Lomb (NYSE:BLCO) Hits New 52-Week High Following Earnings Beat

Bausch + Lomb Corporation (NYSE:BLCO) shares hit a new 52-week high during trading on Thursday following a better than expected earnings announcement. The company traded as high as $21.22 and last traded at $21.2090, with a volume of 297,501 shares trading hands. The stock had previously closed at $20.40.

The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.13. Bausch + Lomb had a negative net margin of 3.21% and a positive return on equity of 4.14%. The firm had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.37 billion. During the same quarter in the prior year, the business posted $0.18 EPS. The business’s revenue was up 7.3% compared to the same quarter last year.

Trending Headlines about Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Raised 2026 guidance: Bausch + Lomb increased its revenue outlook to $5.450 billion-$5.550 billion and adjusted EBITDA guidance to $1.090 billion-$1.140 billion, citing continued momentum from Vision ’27. Bausch + Lomb raises 2026 guidance
• Positive Sentiment: Beat earnings expectations: Third-quarter adjusted EPS was $0.34, well above the $0.21 consensus estimate and up from $0.18 in the year-earlier quarter. The earnings upside was a key driver of the bullish reaction. Bausch + Lomb surpasses Q3 earnings and revenue estimates
• Positive Sentiment: Revenue exceeded forecasts: Quarterly revenue reached approximately $1.375 billion-$1.38 billion, ahead of the $1.37 billion consensus and approximately 7.3% higher year over year. Strong eye-care growth supported the performance. Bausch + Lomb third-quarter earnings results
• Positive Sentiment: Improved profitability: The company swung to a third-quarter profit on an adjusted basis, with earnings substantially ahead of expectations. Management’s earnings call emphasized ongoing operating momentum and the Vision ’27 plan. Bausch + Lomb Q3 2026 earnings call transcript
• Neutral Sentiment: Despite the strong adjusted results, Bausch + Lomb continues to report a negative net margin, so investors will monitor whether revenue growth and the Vision ’27 initiatives translate into sustained GAAP profitability.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BLCO shares. UBS Group began coverage on Bausch + Lomb in a report on Thursday, July 30th. They issued a “buy” rating and a $21.00 price objective for the company. Barclays upgraded Bausch + Lomb to a “strong-buy” rating in a research report on Wednesday, October 7th. Evercore set a $17.00 price target on Bausch + Lomb in a research note on Monday, July 6th. Leerink Partners initiated coverage on shares of Bausch + Lomb in a research report on Wednesday, September 9th. They set an “outperform” rating and a $24.00 price objective for the company. Finally, Weiss Ratings upgraded shares of Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $19.54.

Insider Activity at Bausch + Lomb

In other Bausch + Lomb news, CAO Frederick Munsch sold 52,900 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $16.78, for a total transaction of $887,662.00. Following the completion of the sale, the chief accounting officer directly owned 45,831 shares in the company, valued at $769,044.18. This represents a 53.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $16.50, for a total value of $206,250.00. Following the sale, the director owned 69,792 shares of the company’s stock, valued at $1,151,568. The trade was a 15.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 71,459 shares of company stock valued at $1,194,370. Company insiders own 1.45% of the company’s stock.

Institutional Trading of Bausch + Lomb

Institutional investors and hedge funds have recently modified their holdings of the business. State of Wyoming boosted its stake in Bausch + Lomb by 6.9% in the third quarter. State of Wyoming now owns 13,772 shares of the company’s stock valued at $234,000 after buying an additional 887 shares in the last quarter. Beach Point Capital Management LP bought a new position in Bausch + Lomb in the third quarter valued at about $5,882,000. Counterpoint Mutual Funds LLC acquired a new position in Bausch + Lomb during the third quarter worth about $670,000. Roxbury Financial LLC acquired a new position in Bausch + Lomb during the third quarter worth about $33,000. Finally, Engineers Gate Manager LP acquired a new position in Bausch + Lomb during the second quarter worth about $1,479,000. 11.07% of the stock is currently owned by institutional investors.

Bausch + Lomb Price Performance

The stock has a market cap of $7.39 billion, a P/E ratio of -43.54, a PEG ratio of 0.55 and a beta of 0.56. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.55 and a quick ratio of 1.02. The business’s fifty day moving average price is $17.24 and its 200 day moving average price is $16.66.

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.